GlaxoSmithKline plc (GSK)
| Market Cap | 97.28B |
| Revenue (ttm) | 44.41B |
| Net Income (ttm) | 6.11B |
| Shares Out | 5.38B |
| EPS (ttm) | 0.99 |
| PE Ratio | 38.78 |
| Forward PE | 11.85 |
| Dividend | $2.03 |
| Dividend Yield | 5.28% |
| Trading Day | January 15 |
| Last Price | $38.47 |
| Previous Close | $38.47 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 38.38 |
| Day's Range | 38.21 - 38.66 |
| Day's Volume | 3,100,857 |
| 52-Week Range | 31.08 - 46.66 |
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
PARIS, Jan. 11, 2021 /PRNewswire/ -- Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing El...
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
As the Covid-19 pandemic worsens, the case for dental stocks to buy might not seem too bright. However, this sector is a very broad one, with upside opportunities available right now.
British pharmaceutical company GlaxoSmithKline PLC's (NYSE: GSK) majority-owned subsidiary ViiV Healthcare received the marketing authorization approval for its HIV treatment in the European U...
TOKYO and CAMBRIDGE, England, Dec. 21, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with ...
In the latest trading session, GlaxoSmithKline (GSK) closed at $37.01, marking a -0.88% move from the previous day.
Shares of Vir Biotechnology Inc. gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline said they started dosing patients in a late-stage clinical trial for ...
LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patie...
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV pa...
The vaccine giants will be rethinking the formulation of their coronavirus candidate before a new phase 2 study.
Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an impro...
Sanofi and GlaxoSmithKline pushed back the timeline for rolling out their coronavirus vaccine after finding it didn't work as well in older people. The drugmakers' Friday announcement created ...
Sanofi and GlaxoSmithKline, the French and British pharmaceutical groups, said on Friday that they would delay the launch of their joint coronavirus vaccine until the end of 2021.
Covid vaccine by Sanofi-GSK delayed after disappointing results in older patients
CNBC's Charlotte Reed reports on the setback suffered by Sanofi and GSK in the development of their Covid-19 vaccine, now not expected until the latter part of 2021.
A COVID-19 vaccine being developed by two of the world's biggest vaccine makers, GlaxoSmithKline and Sanofi, has been delayed after it didn't show a strong enough response in older people. Gla...
GlaxoSmithKline said on Friday its goal to produce 1 billion doses of adjuvants - designed to boost COVID-19 vaccine efficacy - in 2021 remained in place but was under review following a devel...
Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in...
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) on Friday reported a delay in their COVID-19 vaccine program as interim results from Phase 1 and 2 trials indicate a low immune resp...
IDEAYA Biosciences is an oncology specialist focused on precision medicine aiming to utilize molecular diagnostics to develop targeted therapeutics with a research focus on synthetic lethality.
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
In the latest trading session, GlaxoSmithKline (GSK) closed at $37.97, marking a +0.34% move from the previous day.
The FDA accepts Glaxo's (GSK) regulatory filing for Nucala to treat patients with chronic rhinosinusitis with nasal polyps. The drug is already approved for three other indications.
Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Ra...
The largest pharmaceutical companies in the world are restructuring. Biopharma represents a far more valuable future than growth-dilutive consumer health revenues. GSK cleared room for next g...
These three could deliver big for investors once their vaccines are approved for sale.
GlaxoSmithKline was downgraded to neutral from buy at UBS, which said the European pharma sector is cheap -- trading at a double-digit discount to the market on forward price-to-earnings -- bu...
WARREN, N.J., Dec. 1, 2020 /PRNewswire/ -- GlaxoSmithKline (LSE/NYSE: GSK) today announced a donation of $1 million to Direct Relief on behalf of consumers who have purchased its consumer heal...
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
Sum-of-parts analysis reveals that GSK is significantly undervalued and its true value is likely to be unlocked by its consumer healthcare JV and subsequent spin-off. The strategy aligns well ...
GlaxoSmithKline remains a high-yield pick in pharma, partially a consequence of several years of little growth and portfolio attrition to generics. Recent waves of drugs falling off-patent lea...
Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.
Dr. Angela Rasmussen explains what investors should know about an under-the-radar coronavirus vaccine developer.
Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
Largest first-time venture capital fund to close in 2020 focused on US/EU biotech
Dr. Angela Rasmussen explains why news from mRNA vaccine trials is so promising and shares tips for investors thinking about buying stocks like Pfizer and Moderna.
FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.
With immobile stock prices and a hangover of legal issues, these CEOs might be glad Wall Street doesn't operate like a democracy.
In this article we present the list of 10 Best Dividend Stocks To Buy According To Billionaire Ken Fisher. Click to skip ahead and see the 5 Best Dividend Stocks To Buy According To Billionai...
Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19.
GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in...
Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. ...
We selected 9 defensive Dividends Aristocrats from 9 Sectors with average dividend yield of 6.7%, including several yielding more than 9%. The stocks in our selection have relatively low corre...
The European Commission has joined the Food and Drug Administration in accepting Zejula as a front-line therapy.
Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.
GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q3 2020 Results - Earnings Call Transcript
Sanofi and GlaxoSmithKline have committed 200 million doses of their experimental coronavirus vaccine to a global effort to distribute shots around the world, the drugmakers said Wednesday. Th...
About GSK
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous syste... [Read more...]
| Industry Drug Manufacturers-General | Founded 1715 |
| CEO Emma Walmsley | Employees 99,437 |
| Stock Exchange NYSE | Ticker Symbol GSK |
Financial Performance
In 2019, GSK's revenue was 33.75 billion, an increase of 9.52% compared to the previous year's 30.82 billion. Earnings were 4.65 billion, an increase of 28.21%.
Analyst Forecasts
According to 6 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 48.50, which is an increase of 26.07% from the latest price.